A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Trial Profile

A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARTAN
  • Sponsors CoLucid Pharmaceuticals
  • Most Recent Events

    • 04 Aug 2017 Results published in an Eli Lilly media release.
    • 04 Aug 2017 Primary endpoint (Proportion of subjects headache pain free at 2 hours post dose) has been met according to an Eli Lilly media release.
    • 10 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top